Daratumumab, Venetoclax, and Azacitidine in Combination with the HAA Regimen as Consolidation Chemotherapy for T-Cell Acute Lymphoblastic Leukemia with High CD38 Expression

Documenti analoghi

• Venetoclax–azacitidine as a bridge to transplant in pediatric relapsed/refractory acute myeloid leukemia: A real-world experience
  di: Sunisha Arora, et al.
  Pubblicazione: (2026-06-01)
• Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center
  di: Ziyi Hao, et al.
  Pubblicazione: (2024-12-01)
• Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review
  di: Xuelian Jin, et al.
  Pubblicazione: (2025-01-01)
• Daratumumab, Venetoclax, and Azacitidine in Combination with the HAA Regimen as Consolidation Chemotherapy for T-Cell Acute Lymphoblastic Leukemia with High CD38 Expression
  di: Lin-sen Feng, et al.
  Pubblicazione: (2025-09-01)
• Advances in non-Hydroxamate based Histone Deacetylase Inhibitors as Anticancer Agents
  di: Nadine W. Nabiha, et al.
  Pubblicazione: (2024-06-01)